Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 3 , Pages 151-159 , September 2007

The current role of photodynamic therapy in oesophageal dysplasia and cancer

References 

  1. Dougherty TJ. Activated dyes as anti-tumour agent. J Natl Cancer. 1974;52:1333–1336
  2. Barr H, Dix AJ, Kendall C, Stone N. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. Aliment Pharmacol Therapeut. 2001;15:311–321
  3. Dougherty TJ. Photosensitisation of malignant tumours. Sem Surg Oncol. 1986;2(1):24–37
  4. Gollnick S, Vaughan L, Henderson B. Generation of effective antitumour vaccines using photodynamic therapy. Cancer Res. 2002;62:1604–1608
  5. Van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology. 2003;207(2):105–113
  6. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5 Aminolevulinic acid for superficial Barrett's cancer and high grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62(1):24–30
  7. Bruce S. Photodynamic therapy: another option in cancer treatment. Clin J Oncol Nurs. 2001 Number 3;5:95–99
  8. Hahn SM, Putt ME, Metz J, et al. Photofrin uptake in the tumour and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res. 2006;12(18):5464–5470
  9. Perry Y, Epperly MW, Fernando HC, et al. Photodynamic therapy induced oesophageal stricture … an animal model: from mouse to pig. J Surg Res. 2005;123(1):67–74
  10. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, Stewart FA. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer. 2003;88(2):283–290
  11. Wagnieres G, Hadjur C, Grosjean P, et al. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra (m-hydroxyphenyl) chlorine. Photochem Photobiol. 1998;68:382–387
  12. Lovat LB, Jamieson NF, Novelli MR, et al. Photodynamic therapy with m-tetrahydroxyphenylchlorin for high grade dysplasia and early cancer in Barrett's columnar lined oesophagus. Gastrointest Endosc. 2005;62(4):617–623
  13. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Flejou JF, Flijou JF. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorine for intramucosal adenocarcinoma and high grade dysplasia in Barrett's oesophagus. Gastrointest Endosc. 2004;59(7):880–889
  14. Barr H, Kendall C, Stone N. Photodynamic therapy for oesophageal cancer: a realistic option. Technol Cancer\Res Treat. 2003;2(1):65–75
  15. Brown SG, Rogowska AZ. New photosensitizers for photodynamic therapy in gastroenterology. Canadian Journal Gastroenterology. 1999;13:389–392
  16. Heier SK, Rothman KA, Heier LM, Rosenthal WS. Photodynamic therapy for obstructing oesophageal cancer: light dosimetry and randomised comparison with Nd:YAG laser therapy. Gastroenterology. 1995;109(1):63–72
  17. Craig C, Macpherson M, Hodgson H, Gray J, Zammit M, Fullarton G. Photodynamic therapy is of benefit in treatment of early oesophageal carcinoma. Gastroenterology. 2006;130(4):414
  18. Panjehpour M, Overhalt BF, Phan MN, Haydek JM. Optimisation of light dosimetry for photodynamic therapy of Barrett's oesophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc. 2005;61(1):13–18
  19. The UK Clinical PDT Study Group, Clinical guidelines for performing photodynamic therapy (PDT) on patients with bronchopulmonary or oesophageal cancer; 2002.
  20. Mordon S, Maunoury V. Using white light during photodynamic therapy: visualization only or treatment?. Eur J Gastroenterol Hepatol. 2006;18(7):765–771
  21. Moghissi K, Dixon K, Hudson E, Stringer M. Photodynamic therapy of oesophageal cancer. Lasers Med Sci. 1995;10:67–71
  22. Litle VR, Luketich JD, Christie NAET-AL>. Photodynamic therapy as palliation for oesophageal cancer: experience in 215 patients. Ann Thorac Surg. 2003;76:1687–1692
  23. McCaughan JS. Photodynamic therapy for obstructive oesophageal malignancies. Diagn Theraput Endosc. 1999;5:174
  24. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Theraput. 2004;20:1125–1131
  25. Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfirmer sodium versus thermal ablation with Nd YAG laser for palliation of oesophageal cancer; a multicentre randomized trial. Gastrointest Endosc. 1996;42:507–512
  26. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Flijou J. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorine for intramucosal adenocarcinoma and HGD in Barrett's oesophagus. Gastrointest Endosc. 2004;59(7):880–889
  27. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of HGD and early cancer in Barrett's oesophagus by means of 5 aminolevulinic acid. Gastroenterology. 1998;114(3):448–455
  28. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol. 2001;30:1415–1425
  29. National Statistics. Cancer Atlas of the UK and Ireland 1991–2000. Office for National Statistics (ONS); 2006.
  30. Cancer Research UK. Information Resource Centre; 2004. Weblink http://info.cancerresearchuk.org.
  31. Parkin DM, Bray F, Ferlay J, et al. Estimating the World cancer burden: globocan. Int J Cancer. 2000;94:163–166
  32. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide Incidence of Eighteen major Cancers in 1985. Int J Cancer. 1993;54:594–606
  33. Phull PS, Salmon CA, Park KGM, Rapson T, Thompson AM, Gilbert FJ. Age threshold for endoscopy and risk of missing upper gastrointestinal malignancy—data from the Scottish Audit of gastric and oesophageal cancer (SAGOC). Aliment Pharmacol Theraput. 2006;23(2):229–233
  34. Gilbert FJ, Park K, Thompson AM. Scottish Audit of Gastric and Oesophageal Cancer Report 1997–2000. A prospective audit 2002. Scottish Audit of Gastric and Oesophageal Cancer Steering Group, Edinburgh.
  35. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic preogression in patients with Barretts oeophaugus. Ann Intern Med. 2000;132:612–620
  36. Van den Bogart , Van Hillergeersberg R, De Bruin RWF, Tilanus H. Barrett's oesophagus: pathophysiology, diagnosis and management. Scand J Gastroenterol. 1998;33:449–453
  37. Wolfsen HC. Present status of photodynamic therapy for high grade dysplasia in Barrett's oesophagus. J Clin Gastroenterol. 2005;39(3):189–202
  38. Tseng EE, Wu TT, Yeo CJ, et al. Barrett's oesophagus with high grade dysplasia: surgical results and long term outcome: an update. J Gastrointest Surg. 2003;7:164–170discussion 170–171
  39. Portale G, Hagen J, Peters J, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202(4):588–596
  40. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77:845–857
  41. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor Lewis oesophagectomy: is there a difference?. Austr NZ J Surg. 1999;69:187–194
  42. Chang LC, Oelschlager BK, Quiroga E, et al. Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surveillance for Barrett's esophagus. J Gastroint Surg. 2006;10(3):341–346
  43. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg. 1996;224(1):66–71
  44. Thomas T, Richards CJ, De Caestecker J, Robinson RJ. High grade dysplasia in Barrett's oesophagus; natural history and review of clinical practise. Aliment Pharmacol Theraput. 2005;21(6):747–755
  45. Brown SB, Walker EA. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5(8):497–508
  46. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddart CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: a randomized controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol. 2004;20(11–12):1289–1296
  47. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomised prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005 July;40(7):750–758
  48. NICE Guidelines 2006. Interventional Procedure Programme. Interventional procedures overview of photodynamic therapy for high grade dysplasia for Barrett's oesophagus.
  49. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's oesophagus with dysplasia and or early stage carcinoma: long term results. Gastrointest Endosc. 2003;58(2):183–188
  50. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett's oesophagus and early oesophageal adenocarcinoma. Mayo Clinic Proc. 2002;77(11):1176–1181
  51. Christophorus , Foroulis N, Thorpe AC. Photodynamic therapy (PDT) in Barrett's oesophagus with dysplasia or early cancer. Eur J Cardio-Thorac Surg. 2006;29(1):30–34
  52. Overholt BF, Lightdale CJ, Wang K, et al. International multicentre partially blinded randomised study into the efficacy of photodynamic therapy (PDT) using Porfirmer sodium (POR) for the ablation of high grade dysplasia (HGD) in Barrett's oesophagus (BE):Results of a 24 month follow up. Gastroenterology. 2003;124(Suppl 1):A20:151
  53. Overholt B, Wang K, Burdick S, et al. A 5 year randomised phase 3 trial of efficacy and safety of photodynamic therapy using porirmer sodium in high grade dysplasia in Barrett's esophagus. Gastroenterology. 2006;130(4):
  54. Gossner L, May A, Sroka R, Stolte M, Hahn EG, Ell C. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer. 1999;86(10):1921–1928
  55. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc Jul. 2005;62(1):24–30
  56. Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348(9027):584–585
  57. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histology of treated Barrett's oesophagus. Am J Pathol. 1998;22:239–245
  58. Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Barr H. Photothermal laser ablation of Barrett's oesophagus and histological evidence of squamous re-epithelialisation. Gut. 1997;41(3):281–284
  59. Van Laethem JL, Cremner M, Peny MO, et al. Complete eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut. 1998;43:747–752
  60. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut. 2000;46(4):574–577
  61. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's oesophagus with high grade dysplasia. Dig Dis bSci. 2003;48(7):1273–1283
  62. Zhang X, Watson DI, Lally C, Bessell JR. Endoscopic ultrasound for pre-operative staging of oesophageal carcinoma. Surg Endosc. 2005;19(12):1618–1621
  63. Sibille A, Lambert R, Souquet JC, Sabben G, Descos F. Long term survival after photodynamic therapy for oesophageal cancer. Gastroenterology. 1995;108(2):337–344
  64. Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for oesophageal neoplasia within Barrett's oesophagus. Gastrointest Endosc. 2001;54(6):682–688
  65. Wolfsen HC, Hemminger LL, Raimomdo M, Woodward TA. Photodynamic therapy and endoscopic mucosal resection for Barrett's dysplasia and early oesophageal adenocarcinoma. South Med J. 2004;97(9):827–830
  66. Edler DG, Baron TH. Endoscopic palliation of malignant dysphagia. Mayo Clinic Proc. 2001;76(7):731–738
  67. Jin M, Yang B, Zhang W, Wang Y. Photodynamic therapy for upper gastrointestinal tumours over the past 10 years. Sem Surg Oncol. 1994;10:111–113
  68. Heier SK, Rothman KA, Heier LM, Rosenthal WS. Photodynamic therapy for obstructing oesophageal cancer: light dosimetry and randomized comparison with Nd:YAG laser therapy. Gastroenterolgy. 1995;109:63–73
  69. Fullarton GM. Photodynamic therapy for advanced oesophageal carcinoma. In: Proceedings of the international congress and symposium (series 255) on photodynamic therapy—applications in gastroenterology and pulmonology. 2004;
  70. O’Donnell CA, Fullarton GM, Watt E, et al. Randomaised clinical trial comparing self expanding metallic stents with plastic endoprotheses in the palliation of oesophageal cancer. Br J Surg. 2002;89:985–992
  71. Zoepf T, Jakobs R, Arnold JC, Apel D, Rosenbaum A, Riemann JF. Photodynamic therapy for palliation of non-resectable bile duct cancer –Preliminary results with a new diode laser system. Am J Gastroenterol. 2001;96(7):2093–2097
  72. Sanfilippo NJ, His A, Denittis AS, et al. Toxicity of photodynamic therapy after combined external beam radiotherapy and intra-luminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med. 2001;28(3):278–281
  73. Maier A, Anegg U, Fell B, et al. Effect of photodynamic therapy in a multimodal approach for advanced carcinoma of the gastroesophageal junction. Lasers Surg Med. 2000;26(5):461–466
  74. Schaffer M, Erti-Wagner , Schaffer PM, et al. The application of Photofrin 2 as a sensitising agent for ionizing radiation—a new approach in tumour therapy. Curr Med Chem. 2005;12(10):1209–1215
  75. Schaffer M, Erti-Wagner B, Schaffer PM, et al. Feasibility of Photofrin 2 as a radiosensitizing agent in solid tumous—preliminary results. Oncology. 2006;29(11):514–519
  76. O’Donnell CA, Gray J, Hodgson H, MacPherson M, Zammit M, Fullarton G. A cost comparison of photodynamic therapy and metallic stents in the palliation of oesophageal cancer. Photodyn Therapy Photodiagn. 2007;4(1):65–70
  77. Peng Q, Warloe T, Moan J, et al. Antitumour effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of Photofrin in human tumour xenografts. Cancer Res. 2001;61(15):5824–5832

PII: S1572-1000(07)00056-7

doi: 10.1016/j.pdpdt.2007.04.003

Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 3 , Pages 151-159 , September 2007

Article Tools

* Image Usage & Resolution